The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Sayegh MH, Carpenter CB: Transplantation 50 years later – progress, challenges, and promises. N. Engl. J. Med.351, 2761–2766 (2004).
  Google Scholar
• 2  Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 346, 580–590 (2002).
  MedlineGoogle Scholar
• 3  Raine AE: Hypertension and ischaemic heart disease in renal transplant recipients. Nephrol. Dial. Transplant. 10 (Suppl. 1), 95–100 (1995).
  MedlineGoogle Scholar
• 4  Halloran PF: Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med.351, 2715–2729 (2004).•  Recent review on immunosuppressive agents for kidney transplantation.
  Medline CASGoogle Scholar
• 5  Evans WE, McLeod HL: Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med.348, 538–549 (2003).•  Comprehensive review on pharmacogenomics.
  Medline CASGoogle Scholar
• 6  Borel JF, Feurer C, Gubler HU, Stahelin H: Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions6, 468–475 (1976).
  Medline CASGoogle Scholar
• 7  Kino T, Hatanaka H, Miyata S et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo)40, 1256–1265 (1987).
  Medline CASGoogle Scholar
• 8  Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL: Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) in organ transplantation. Drugs61, 1957–2016 (2001).
  Medline CASGoogle Scholar
• 9  Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet.43, 623–653 (2004).
  Google Scholar
• 10  Hesselink DA, Smak Gregoor PJ, Weimar W: The use of cyclosporine in renal transplantation. Transplant. Proc. 36, S99-S106 (2004).
  Google Scholar
• 11  Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation73, 775–782 (2002).
  Medline CASGoogle Scholar
• 12  Klupp J, Holt DW, van Gelder T: How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl. Immunol.9, 211–214 (2002).
  MedlineGoogle Scholar
• 13  Levy G, Burra P, Cavallari A et al.: Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation73, 953–959 (2002).
  Medline CASGoogle Scholar
• 14  Mahalati K, Belitsky P, West K et al.: Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J. Am. Soc. Nephrol. 12, 828–833 (2001).
  Medline CASGoogle Scholar
• 15  Clase CM, Mahalati K, Kiberd BA et al.: Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am. J. Transplant.2, 789–795 (2002).
  Medline CASGoogle Scholar
• 16  Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther.75, 13–33 (2004).
  Medline CASGoogle Scholar
• 17  Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem.268, 6077–6080 (1993).
  Medline CASGoogle Scholar
• 18  Zhang Y, Benet LZ: The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet.40, 159–168 (2001).
  Medline CASGoogle Scholar
• 19  Paine MF, Leung LY, Lim HK et al.: Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J. Pharmacol. Exp. Ther.301,174–186 (2002).
  Medline CASGoogle Scholar
• 20  Ueda K, Okamura N, Hirai M et al.: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem.267, 24248–24252 (1992).
  Medline CASGoogle Scholar
• 21  Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem.62, 385–427 (1993).
  Medline CASGoogle Scholar
• 22  Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood83, 2451–2458 (1994).
  Medline CASGoogle Scholar
• 23  Randolph GJ, Beaulieu S, Pope M et al.: A physiologic function for P-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl Acad. Sci. USA95, 6924–6929 (1998).
  Medline CASGoogle Scholar
• 24  Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther.43, 630–635 (1988).
  Medline CASGoogle Scholar
• 25  Karanam BV, Vincent SH, Newton DJ, Wang RW, Chiu SH: FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug. Metab. Dispos.22,811–814 (1994).
  Medline CASGoogle Scholar
• 26  Aoyama T, Yamano S, Waxman DJ et al.: Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem.264, 10388–10395 (1989).
  CASGoogle Scholar
• 27  Wojnowski L: Genetics of the variable expression of CYP3A in humans. Ther. Drug Monit.26, 192–199 (2004).
  Medline CASGoogle Scholar
• 28  Ozdemir V, Kalowa W, Tang BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics10, 373–388 (2000).
  Medline CASGoogle Scholar
• 29  Lown KS, Kolars JC, Thummel KE et al.: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos.22, 947–955 (1994).
  Medline CASGoogle Scholar
• 30  Lown KS, Mayo RR, Leichtman AB et al.: Role of intestinal P-glycoprotein (MDR1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther.62, 248–260 (1997).
  Medline CASGoogle Scholar
• 31  Hustert E, Haberl M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics11, 773–779 (2001).
  Medline CASGoogle Scholar
• 32  Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet.27, 83–91 (2001).
  Google Scholar
• 33  Burk O, Tegude H, Koch I et al.: Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem.277, 24280–24288 (2002).
  Medline CASGoogle Scholar
• 34  Kaplan B, Lown K, Craig R et al.: Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation67, 333–335 (1999).
  Medline CASGoogle Scholar
• 35  Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K: Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin. Pharmacol. Ther.68, 98–103 (2000).
  Medline CASGoogle Scholar
• 36  Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K: Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin. Pharmacol. Ther.75, 352–361 (2004).
  Medline CASGoogle Scholar
• 37  Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K: Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. Pharmacol. Ther.69, 308–316 (2001).
  Medline CASGoogle Scholar
• 38  Goto M, Masuda S, Saito H et al.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12, 451–457 (2002).
  Medline CASGoogle Scholar
• 39  Kolars JC, Awni WM, Merion RM, Watkins PB: First-pass metabolism of cyclosporin by the gut. Lancet338, 1488–1490 (1991).
  Medline CASGoogle Scholar
• 40  Tuteja S, Alloway RR, Johnson JA, Gaber AO: The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation71, 1303–1307 (2001).
  Medline CASGoogle Scholar
• 41  Shimada T, Terada A, Yokogawa K et al.: Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 74, 1419–1424 (2002).
  Medline CASGoogle Scholar
• 42  Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther.52, 453–457 (1992).
  Medline CASGoogle Scholar
• 43  Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther.58, 15–19 (1995).
  Medline CASGoogle Scholar
• 44  Floren LC, Bekersky I, Benet LZ et al.: Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther.62, 41–49 (1997).
  Medline CASGoogle Scholar
• 45  Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97, 3473–3478 (2000).
  Medline CASGoogle Scholar
• 46  Johne A, Kopke K, Gerloff T et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584–594 (2002).
  Medline CASGoogle Scholar
• 47  Tanabe M, Ieiri I, Nagata N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther.297, 1137–1143 (2001).
  Medline CASGoogle Scholar
• 48  Hitzl M, Drescher S, van der Kuip H et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics11, 293–298 (2001).
  Medline CASGoogle Scholar
• 49  Nakamura T, Sakaeda T, Horinouchi M et al.: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther.71, 297–303 (2002).
  Medline CASGoogle Scholar
• 50  Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European–Americans and African–Americans. Clin. Pharmacol. Ther.70, 189–199 (2001).
  Medline CASGoogle Scholar
• 51  Siegmund W, Ludwig K, Giessmann T et al.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther.72, 572–583 (2002).
  Medline CASGoogle Scholar
• 52  Gerloff T, Schaefer M, Johne A et al.: MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol.54, 610–616 (2002).
  Medline CASGoogle Scholar
• 53  Drescher S, Schaeffeler E, Hitzl M et al.: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol.53, 526–534 (2002).
  Medline CASGoogle Scholar
• 54  Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics13, 89–95 (2003).
  Medline CASGoogle Scholar
• 55  Kroetz DL, Pauli-Magnus C, Hodges LM et al.: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics13, 481–494 (2003).
  Medline CASGoogle Scholar
• 56  Yi S-Y, Hong K-S, Lim H-S et al.: A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther.76, 418–427 (2004).
  Medline CASGoogle Scholar
• 57  Schaeffeler E, Eichelbaum M, Brinkmann U et al.: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet358,383–384 (2001).
  Medline CASGoogle Scholar
• 58  Ameyaw MM, Regateiro F, Li T et al.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics11, 217–221 (2001).
  Medline CASGoogle Scholar
• 59  Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst.90, 1225–1229 (1998).
  Medline CASGoogle Scholar
• 60  Amirimani B, Walker AH, Weber BL, Rebbeck TR: Response: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst.91, 1588–1590 (1999).
  Medline CASGoogle Scholar
• 61  Spurdle AB, Goodwin B, Hodgson E et al.: The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics12, 355–366 (2002).
  Medline CASGoogle Scholar
• 62  van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem.48, 1668–1671 (2002).
  Medline CASGoogle Scholar
• 63  Westlind-Johnsson A, Malmebo S, Johansson A et al.: Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug. Metab. Dispos.31, 755–761 (2003).
  Medline CASGoogle Scholar
• 64  Dally H, Bartsch H, Jager B et al.: Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett.207, 95–99 (2004).
  Medline CASGoogle Scholar
• 65  Paulussen A, Lavrijsen K, Bohets H et al.: Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics10, 415–424 (2000).
  Medline CASGoogle Scholar
• 66  von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem.47, 1048–1052 (2001).
  MedlineGoogle Scholar
• 67  Hesselink DA, van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther.74, 245–254 (2003).
  Medline CASGoogle Scholar
• 68  Kuzuya T, Kobayashi T, Moriyama N et al.: Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation76, 865–868 (2003).
  Medline CASGoogle Scholar
• 69  Hesselink DA, Van Gelder T, van Schaik RHN et al.: Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther.76, 545–556 (2004).•  Demonstrates an effect of the CYP3A4*1B SNP on CsA pharmacokinetics by use of nonlinear mixed-effects modeling.
  Medline CASGoogle Scholar
• 70  Hebert MF, Dowling AL, Gierwatowski C et al.: Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics13,661–674 (2003).••  Demonstrates an effect of ABCB1 genotype on the risk of developing CNI-related nephrotoxicity after liver transplantation.
  Medline CASGoogle Scholar
• 71  Balram C, Sharma A, Sivathasan C, Lee EJ: Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlates. Br. J. Clin. Pharmacol.56, 78–83 (2003).
  Medline CASGoogle Scholar
• 72  Mai I, Stormer E, Goldammer M et al.: MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J. Clin. Pharmacol.43, 1101–1107 (2003).
  Medline CASGoogle Scholar
• 73  Anglicheau D, Thervet E, Etienne I et al.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther.75, 422–433 (2004).
  Medline CASGoogle Scholar
• 74  Haufroid V, Mourad M, van Kerckhove V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant recipients. Pharmacogenetics14,147–154 (2004).
  Medline CASGoogle Scholar
• 75  Yates CR, Zhang W, Song P et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol.43,555–664 (2003).
  Medline CASGoogle Scholar
• 76  Bonhomme-Faivre L, Devocelle A, Saliba F et al.: MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients. Transplantation78, 21–25 (2004).
  Medline CASGoogle Scholar
• 77  Min DI, Ellingrod VL: C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit.24, 400–404 (2002).
  Medline CASGoogle Scholar
• 78  MacPhee IA, Fredericks S, Tai T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation74, 1486–1489 (2002).
  Medline CASGoogle Scholar
• 79  Zheng H, Webber S, Zeevi A et al.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant.3, 477–483 (2003).
  Medline CASGoogle Scholar
• 80  Anglicheau D, Verstuyft C, Laurent-Puig P et al.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol.14, 1889–1896 (2003).•  Demonstrates an association between ABCB1 haplotypes and Tac dose requirement.
  Medline CASGoogle Scholar
• 81  Mai I, Perloff ES, Bauer S et al.: MDR1 haplotypes derived from exons 21 and 26 do not influence the steady-state pharmacokinetics of tacrolimus in renal transplant recipients. Br. J. Clin. Pharmacol.58, 548–553 (2004).
  Medline CASGoogle Scholar
• 82  Tsuchiya N, Satoh S, Tada H et al.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation78, 1182–1187 (2004).
  Medline CASGoogle Scholar
• 83  Goto M, Masuda S, Kiuchi T et al.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics14, 471–478 (2004).
  Medline CASGoogle Scholar
• 84  Zheng H, Zeevi A, Schuetz E et al.: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 44, 135–140 (2004).
  Medline CASGoogle Scholar
• 85  Rivory LP, Qin H, Clarke SJ et al.: Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur. J. Clin. Pharmacol.56, 395–398 (2000).
  Medline CASGoogle Scholar
• 86  Min DI, Ellingrod VL: Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit.25,305–309 (2003).
  Medline CASGoogle Scholar
• 87  Undre NA, Schafer A: Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant. Proc.30, 1261–1263 (1998).
  Medline CASGoogle Scholar
• 88  Thervet E, Anglicheau D, King B et al.: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation76, 1233–1235 (2003).
  Medline CASGoogle Scholar
• 89  Macphee IA, Fredericks S, Mohamed M et al.: Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south asians. Transplantation79, 499–502 (2005).
  Medline CASGoogle Scholar
• 90  Macphee IA, Fredericks S, Tai T et al.: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant.4, 914–919 (2004).••  Demonstrates that CYP3A5 expressors reach their Tac target concentrations later despite TDM, and that these individuals experience acute rejection earlier after transplantation.
  Medline CASGoogle Scholar
• 91  Koziolek MJ, Riess R, Geiger H, Thevenod F, Hauser IA: Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int.60, 156–166 (2001).
  Medline CASGoogle Scholar
• 92  Hauser IA, Schaeffeler E, Gauer S et al.: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol.16, 1501–1511 (2005).••  Identifies the ABCB1 genotype of the kidney donor as a major risk factor for the development of CsA-related nephrotoxicity after transplantation.
  Medline CASGoogle Scholar
• 93  Yamauchi A, Ieiri I, Kataoka Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation74, 571–572 (2002).
  Medline CASGoogle Scholar
• 94  Asano T, Takahashi KA, Fujioka M et al.: ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics13, 675–682 (2003).
  Medline CASGoogle Scholar
• 95  Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, Grabarek J: P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J. Clin. Periodontol.31, 758–763 (2004).
  Medline CASGoogle Scholar
• 96  Andrews PA, Sen M, Chang RWS: Racial variation in dosage requirements of tacrolimus. Lancet348, 1446 (1996).
  Google Scholar
• 97  Christians U, Jacobsen W, Benet LZ, Lampen A: Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet.41, 813–851 (2002).
  Medline CASGoogle Scholar
• 98  Smak Gregoor PJH, de Sévaux RG, Hené RJ et al.: Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 68, 1603–1606 (1999).
  MedlineGoogle Scholar
• 99  Hesselink DA, Ngyuen H, Wabbijn M et al.: Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br. J. Clin. Pharmacol. 56, 327–330 (2003).
  Medline CASGoogle Scholar
• 100  Williams PA, Cosme J, Matak Vinkovic D et al.: Crystal structures of human cytochrome P450 3A4 bound to metapyrone and progesterone. Science305, 683–686 (2004).
  Medline CASGoogle Scholar
• 101  Anglicheau D, Le Corre D, Lechaton S et al.: Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant.5, 595–603 (2005).•  First study to investigate the effects of SNPs in MDR1 and CYP3A on the dose requirement of sirolimus.
  Medline CASGoogle Scholar
• 201  www.imm.ki.se/CYPalleles Website of the Human CYP Allele Nomenclature Committee (Accessed June 2005).
  Google Scholar